


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (Original) A compound represented by formula (I)



wherein is a single bond or double bond,


is  $\alpha$ -configuration,  $\beta$ -configuration or a voluntary mixture of  $\alpha$ -configuration and  $\beta$ -configuration,

D is -COOR<sup>1</sup> or tetrazoryl,

R<sup>1</sup> is hydrogen or C1-4 alkyl,

G is ringA or C1-4 alkylene,

ringA is



R<sup>2</sup> is a halogen atom, C1-4 alkyl or C1-4 alkoxy,

p is 0 or an integer of 1-4,


when p is 2 or more, plural R<sup>2</sup>'s are the same or different,

Y is a single bond or -S-,

T is oxygen or sulfur,

X is -CH<sub>2</sub>-, -O- or -S-,

ringB is C3-7 cycloalkyl optionally substituted,



wherein  $R^3$  is (1) a halogen atom, (2) C1-4 alkyl optionally substituted with 1-5 of halogen atom(s), (3) C1-4 alkoxy optionally substituted with 1-5 of halogen atom(s), (4) C1-4 alkyl substituted with C1-4 alkoxy, (5) phenyl or (6) 3- to 15- membered mono-, bi- or tri-heterocyclic aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atom(s) which may be partially or fully saturated, and (5) phenyl or (6) heterocyclic aryl in  $R^3$  is optionally substituted with 1-3 of (a) halogen atom(s), (b) C1-4 alkyl, (c) C1-4 alkoxy and/or (d) nitro,

$q$  is 0 or an integer of 1-5,

when  $q$  is 2 or more, plural  $R^3$ 's are the same or different,

$n$  is an integer of 1-4,

a salt thereof, a solvate thereof, a cyclodextrin clathrate thereof, or a prodrug thereof.

**2. (Original)** The compound according to claim 1, which is selected from the group consisting of:

- (1) 4-[(2-[(4S)-4-[(1E,3S)-4-(3-ethylphenyl)-3-hydroxybut-1-enyl]-2-oxo-1,3-thiazolidine-3-yl]ethyl)sulfanyl]butanoic acid,
- (2) 4-[(2-[(4S)-4-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidine-3-yl]ethyl)sulfanyl]butanoic acid,
- (3) 4-{[2-((4S)-4-[(1E,3S)-4-[4-fuloro-3-(trifluoromethyl)phenyl]-3-hydroxybut-1-enyl]-2-oxo-1,3-thiazolidine-3-yl)ethyl}sulfanyl]butanoic acid,
- (4) 4-[(2-[(4S)-4-[(1E,3S)-4-(3,5-difluorophenyl)-3-hydroxybut-1-enyl]-2-oxo-1,3-thiazolidine-3-yl]ethyl)sulfanyl]butanoic acid,
- (5) 4-[(2-[(4S)-4-[(1E,3S)-3-hydroxy-4-(3-propylphenyl)but-1-enyl]-2-oxo-1,3-thiazolidine-3-yl]ethyl)sulfanyl]butanoic acid,
- (6) 4-[(2-[(4S)-4-[(1E,3S)-4-(3-ethyl-4-fluorophenyl)-3-hydroxybut-1-enyl]-2-oxo-1,3-thiazolidine-3-yl]ethyl)sulfanyl]butanoic acid,
- (7) 4-[(2-[(4S)-4-[(1E,3S)-4-(3,4-difluorophenyl)-3-hydroxybut-1-enyl]-2-oxo-1,3-thiazolidine-3-yl]ethyl)sulfanyl]butanoic acid.

(8) 4-{{2-((4S)-4-((1E,3S)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]but-1-enyl)-2-oxo-1,3-thiazolidine-3-yl}ethyl}sulfanyl]butanoic acid,

(9) 4-[2-{{(4S)-4-[(1E,3S)-4-(4-fuloro-3-methylphenyl)-3-hydroxybut-1-enyl]-2-oxo-1,3-thiazolidine-3-yl}ethyl}sulfanyl]butanoic acid,

(10) 4-[(2-{{(4S)-4-[(1E,3S)-4-(3-fulorophenyl)-3-hydroxybut-1-enyl]-2-oxo-1,3-thiazolidine-3-yl}ethyl}sulfanyl]butanoic acid,

(11) 4-[(2-{{(4S)-4-[(1E,3S)-4-(3-chloro-4-fulorophenyl)-3-hydroxybut-1-enyl]-2-oxo-1,3-thiazolidine-3-yl}ethyl}sulfanyl]butanoic acid,

(12) 4-{{2-((4S)-4-((1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl)-2-oxo-1,3-thiazolidine-3-yl}ethyl}sulfanyl]butanoic acid,

(13) 7-{{(2R)-2-[(1E,3S)-4-(4-fulorophenyl)-3-hydroxybut-1-enyl]-5-thioxopyrrolidine-1-yl}heptanoic acid,

(14) 7-{{(2R)-2-[(1E,3S)-4-(3,5-difulorophenyl)-3-hydroxybut-1-enyl]-5-thioxopyrrolidine-1-yl}heptanoic acid,

(15) 7-((2R)-2-{{(1E,3S)-4-[4-fuloro-3-(trifluoromethyl)phenyl]-3-hydroxybut-1-enyl}-5-thioxopyrrolidine-1-yl)heptanoic acid,

(16) 7-{{(2R)-2-[(1E,3S)-4-(4-fuloro-3-methylphenyl)-3-hydroxybut-1-enyl]-5-thioxopyrrolidine-1-yl}heptanoic acid,

(17) 7-{{(2R)-2-[(1E,3S)-4-(3-ethyl-4-fulorophenyl)-3-hydroxybut-1-enyl]-5-thioxopyrrolidine-1-yl}heptanoic acid,

(18) 7-((2R)-2-{{(1E,3S)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]but-1-enyl}-5-thioxopyrrolidine-1-yl)heptanoic acid,

(19) 7-{{(2R)-2-[(1E,3S)-4-(3-fulorophenyl)-3-hydroxybut-1-enyl]-5-thioxopyrrolidine-1-yl}heptanoic acid,

(20) 7-{{(2R)-2-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-5-thioxopyrrolidine-1-yl}heptanoic acid,


(21) 7-{{(2R)-2-[(1E,3S)-4-(3,4-difulorophenyl)-3-hydoroxybut-1-enyl]-5-thioxopyrrolidine-1-yl}heptanoic acid,

(22) 7-{{(2R)-2-[(1E,3S)-4-(3-chloro-4-fulorophenyl)-3-hydroxybut-1-enyl]-5-thioxopyrrolidine-1-yl}heptanoic acid,

(23) 7-{{(2R)-2-[(1E,3S)-4-(3-ethylphenyl)-3-hydroxybut-1-enyl]-5-thioxopyrrolidine-1-yl}heptanoic acid,


(24) 7-((2R)-2-[(1E,3S)-3-hydroxy-4-(3-propylphenyl)but-1-enyl]-5-thioxopyrrolidine-1-yl}heptanoic acid.

3. (Original) The compound according to claim 1, which is represented by formula (I-1):




wherein  $G^1$  is  $ringA^1$  or C1-4 alkylene,

$ringA^1$  is



wherein left-pointing arrow represents binding to S, and right-pointing arrow represents binding to  $COOR^1$ ,

$ringB^1$  is C3-7 cycloalkyl,



$ringB^1$  may be substituted with a halogen atom, C1-4 alkyl, phenyl, methoxymethyl, trifluoromethyl and/or trifluoromethoxy,

other symbols have the same meanings as described in claim 1, and

wherein when T is oxygen, X is  $-CH_2-$ , and

when n is an integer of 2-4,  $G^1$  is  $ringA^1$ .

4. (Original) The compound according to claim 3, which is selected from the group consisting of:

- (1) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-phenylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprostan-13-enoic acid,
- (2) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-ethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprostan-13-enoic acid,

- (3) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-chloro-4-fulorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (4) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (5) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-trifuloromethoxyphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (6) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fuloro-3-phenylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (7) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fuloro-3-methylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (8) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3,5-difulorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (9) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-fulorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (10) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fuloro-3-trifuloromethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (11) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-trifuloromethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (12) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3,4-difulorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (13) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-phenyl-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (14) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-propylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (15) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-methoxymethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (16) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-ethyl-4-fulorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid,
- (17) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-phenyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprost-13-ene,
- (18) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-methylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprost-13-ene,

(19) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fulorophenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprostan-13-ene,

(20) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprostan-13-ene,

(21) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-phenylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprostan-13-ene,

(22) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-phenylphenyl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(23) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(24) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fuloro-3-phenylphenyl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(25) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-ethylphenyl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(26) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-methylphenyl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(27) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-trifuloromethoxyphenyl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(28) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fuloro-3-phenylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(29) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-ethylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(30) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(31) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-trifuloromethoxyphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,


(32) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-chloro-4-fulorophenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(33) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-cyclopropyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,


(34) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-cyclohexyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

(35) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fulorophenyl)-5-(5-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,  
(36) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-cyclobutyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,  
(37) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-chlorophenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,  
(38) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-cycloheptyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,  
(39) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(indane-2-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,  
(40) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(tetrahydropyran-4-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,  
(41) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(7-methylnaphthalene-2-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,  
(42) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fulorophenyl)-17,18,19,20-tetranol-5,10-dithia-8-azaprost-13-enoic acid,  
(43) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fulorophenyl)-17,18,19,20-tetranol-6-thia-8-azaprost-13-enoic acid,  
(44) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-methylphenyl)-17,18,19,20-tetranol-6-thia-8-azaprost-13-enoic acid, and  
(45) (15 $\alpha$ ,13E)-9-thioxo-15-hydroxy-16-(4-fulorophenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid.

5. (Original) The compound according to claim 1, which is represented by formula (I-2):



wherein G<sup>2</sup> is



wherein left-pointing arrow represents binding to  $-(CH_2)_2-$ , and right-pointing arrow represents binding to D,

$R^4$  is (1) a halogen atom, (2) C1-4 alkyl (3) C1-4 alkoxy, (4) C1-4 alkyl optionally substituted with 1-5 of halogen atom(s), (5) C1-4 alkoxy optionally substituted with 1-5 of halogen atom(s), (6) phenyl or (7) 3- to 15- membered mono-, bi- or tri-heterocyclic aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atom(s) which may be partially or fully saturated, and (6) phenyl or (7) heterocyclic in the  $R^4$  may be substituted with 1-3 of (a) a halogen atom(s), (b) C1-4 alkyl (c) C1-4 alkoxy and/or (d) nitro,

$r$  is an integer 1 to 5, and

other symbols have the same meanings as described in claim 1.

**6. (Original)** The compound according to claim 5, which is selected from the group consisting of:

- (1)  $(15\alpha,13E)$ -1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3,5-dimethylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid,
- (2)  $(15\alpha,13E)$ -1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(benzothiazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid,
- (3)  $(15\alpha,13E)$ -1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(4-fulorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid,
- (4)  $(15\alpha,13E)$ -9-oxo-15-hydroxy-16-(3-(5-methylbenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,
- (5)  $(15\alpha,13E)$ -1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(5-methylbenzoxazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid,
- (6)  $(15\alpha,13E)$ -9-oxo-15-hydroxy-16-(3-(6-methylbenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,
- (7)  $(15\alpha,13E)$ -1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(6-methylbenzoxazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid,

(8) (15 $\alpha$ ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(4-methylbenzothiazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

(9) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(4-methylbenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,

(10) (15 $\alpha$ ,13E)-1,6-(2-fuloro-1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

(11) (15 $\alpha$ ,13E)-1,6-(3-methyl-1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

(12) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(5,7-dimethylbenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,

(13) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(5-chlorobenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,

(14) (15 $\alpha$ ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(5-chlorobenzothiazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

(15) (15 $\alpha$ )-9-oxo-15-hydroxy-16-(3-(2,4-dimethylphenyl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,

(16) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(3,4-dimethylphenyl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,

(17) (15 $\alpha$ ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3,4-difulorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

(18) (15 $\alpha$ ,13E)-1,6-(2-methyl-1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

(19) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(5-chlorobenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,

(20) (15 $\alpha$ ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methyl-4-fulorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

(21) (15 $\alpha$ ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-chloro-4-fulorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

(22) (15 $\alpha$ ,13E)-1,6-(3-methoxy-1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

(23) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-trifuloromethoxyphenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid,

- (24) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3,5-difulorophenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid,
- (25) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(phenyl)phenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid,
- (26) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(4-fulorophenyl)phenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid, and
- (27) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-phenyl-4-fulorophenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid.

7. **(Currently Amended)** A pharmaceutical composition comprising the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof, a cyclodextrin clathrate thereof, or a prodrug thereof, and a pharmaceutically acceptable carrier.

8. **(Currently Amended)** An EP4 agonist comprising the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof, and a pharmaceutically acceptable carrier.

9. **(Original)** A method for preventing and/or treating EP4-mediated disease, which comprises administrating to a mammal an effective amount of the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof.

Claim 10. **(Canceled)**